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Abstract
Introduction Perhaps the major challenge in developing more
effective therapeutic strategies for the treatment of breast
cancer patients is confronting the heterogeneity of the disease,
recognizing that breast cancer is not one disease but multiple
disorders with distinct underlying mechanisms. Gene-
expression profiling studies have been used to dissect this
complexity, and our previous studies identified a series of
intrinsic subtypes of breast cancer that define distinct
populations of patients with respect to survival. Additional work
has also used signatures of oncogenic pathway deregulation to
dissect breast cancer heterogeneity as well as to suggest
therapeutic opportunities linked to pathway activation.
Methods We used genomic analyses to identify relations
between breast cancer subtypes, pathway deregulation, and
drug sensitivity. For these studies, we use three independent
breast cancer gene-expression data sets to measure an
individual tumor phenotype. Correlation between pathway
status and subtype are examined and linked to predictions for
response to conventional chemotherapies.
Results We reveal patterns of pathway activation characteristic
of each molecular breast cancer subtype, including within the
more aggressive subtypes in which novel therapeutic
opportunities are critically needed. Whereas some oncogenic
pathways have high correlations to breast cancer subtype (RAS,
CTNNB1, p53, HER1), others have high variability of activity
within a specific subtype (MYC, E2F3, SRC), reflecting biology
independent of common clinical factors. Additionally, we
combined these analyses with predictions of sensitivity to
commonly used cytotoxic chemotherapies to provide additional
opportunities for therapeutics specific to the intrinsic subtype
that might be better aligned with the characteristics of the
individual patient.
Conclusions Genomic analyses can be used to dissect the
heterogeneity of breast cancer. We use an integrated analysis
of breast cancer that combines independent methods of
genomic analyses to highlight the complexity of signaling
pathways underlying different breast cancer phenotypes and to
identify optimal therapeutic opportunities.
ER: estrogen receptor; PR: progesterone receptor; RMA: Robust Multichip Average.
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Introduction
The practice of oncology continually faces the challenge of
matching the right therapeutic regimen with the right patient,
balancing relative benefit with risk to achieve the most favora-
ble outcome. This challenge is often daunting, with marginal
success rates in many advanced disease contexts, likely
reflecting the enormous complexity of the disease process
coupled with an inability to guide properly the use of available
therapeutics. The clinical and molecular characteristics of an
individual tumor are the result of multiple mutations acquired
over time and continued evolution of the responses to environ-
ment, all of this in the context of the inherited germline varia-
tions that affect tumor development. The complexity of
carcinogenesis thus leads to immense natural heterogeneity in
tumor phenotypes, disease outcomes, and response to
therapies.
New technologies offer the potential of genome-wide biologic
data that may serve as powerful adjuncts to currently available
clinical and biochemical markers in dissecting cancer biology.
Integrating clinicopathologic variables with genome-wide data
may begin to characterize the complexity of disease, thus iden-
tifying discrete subsets of pathology that have not been recog-
nized before the use of genomic data. The ability to find
structure in the data, in the form of patterns of gene expression
that provide snapshots of gene activity in a cell or tissue sam-
ple at a given instant of time, is transforming biology from an
observational science into a data-intensive quantitative sci-
ence. The dimension and complexity of such data provide
opportunity to uncover patterns and trends that can distin-
guish subtle phenotypes in ways that traditional methods
cannot.
One approach is the use of DNA microarray analysis to define
subgroups of breast cancer patients based on unique profiles
of gene expression that have distinct clinical outcomes [1,2].
A particular focus has been placed on the basal-like subtype,
which defines a group of patients with poor outcome. The
Basal-like subtype is negative for expression of common path-
ologic measurements including estrogen receptor, progester-
one receptor, and HER2 receptor. This is also the
predominant subtype observed in cancers of patients with
BRCA1 mutations [1]. In addition, the luminal B subtype also
represents a poor-prognosis group with few therapeutic
options. This subtype correlates positively with clinical meas-
urements such as ER expression, high proliferation index, and
poor tumor grade [3]. Other work has made use of gene-
expression profiles to develop genomic signatures of cell-sig-
naling pathways that can then serve as guides for directing the
use of targeted therapeutic agents [4-6]. Additionally, expres-
sion signatures have also been developed to predict the sen-
sitivity to a variety of standard-of-care cytotoxic
chemotherapeutic drugs [7,8].
Although in principle these two approaches could be used
independently, we also recognize the opportunity for synergy,
whereby a combination of the two methods for analysis of
breast cancer has the potential to dissect further the hetero-
geneity of the disease. Here we describe an integrated analy-
sis of breast cancers that brings these distinct forms of
expression analysis together, both to highlight the complexity
evident within the subtypes and, at the same time, to identify
therapeutic opportunities specific to each subtype.
Materials and methods
We made use of three publicly available breast tumor data
sets profiled on Affymetrix U133a microarrays: Wang and col-
leagues [9] [GEO:GSE2034], Miller and colleagues [10]
[GEO:GSE3494], and Pawitan and associates
[GEO:GSE1456]. We then applied multiple different expres-
sion predictors that used different methods. These predictors
were all derived by using other microarray data sets, and thus,
the data sets used here represent true test sets. These data
sets were individually normalized by using DWD (Distance
Weighted Discrimination) and then used as described later.
Predicted subtypes, pathways, and chemosensitivities were
performed on each data set independently, and then these
results were combined to form a single data set for analysis.
Analysis of expression data to define intrinsic subtypes
Breast cancer subtypes were assigned as described in Hu
and others [2]. The training set of 259 samples representing
the five subtypes (Luminal A, Luminal B, HER2-enriched,
Basal-like, and Normal-like) and 306 genes previously identi-
fied were used to build a corresponding set of five centroids
[2]. The test sets were first adjusted for platform effects by
centering each feature to have a median log2 value of zero
within each set. Features were assigned Entrez Gene identifi-
ers, and duplicate identifiers were collapsed to the mean. Each
test case was then compared with the five standardized cen-
troids by using Spearman's rank correlation. A test case was
then assigned the subtype of the nearest centroid.
Analysis of expression data for predicting pathway 
activation
Pathway analysis made use of previously described methods
[4,6]. In brief, before statistical modeling, gene-expression
data are filtered to exclude probe sets with signals present at
background noise levels and for probe sets that do not vary
significantly across samples. Data sets are normalized prior to
binary regression using distance weighted discrimination [11].
A signature represents a group of genes that together exhibit
a consistent pattern of expression in relation to an observable
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phenotype. Each signature summarizes its constituent genes
as a single expression profile and is here derived as the first
principal component of that set of genes (the factor corre-
sponding to the largest singular value), as determined by a sin-
gular value decomposition. Given a training set of expression
vectors representing two biologic states, a binary probit
regression model is estimated by using bayesian methods.
Importantly, when predicting the pathway activation of cancer
cell lines or tumor samples, the gene selection, identification,
and regression model are based on the training data only and
then projected into the test data such as additional cell-line or
tumor-expression data. This leads to evaluations of predictive
probabilities of each of the two states for each case in the
validation set. Bayesian fitting of binary probit regression mod-
els to the training data permits an assessment of the relevance
of the gene-expression signatures in within-sample classifica-
tion and provides an estimation and uncertainty. Relative pre-
dictions from the binary regression models are centered, and,
in some cases, hierarchic cluster is performed by using Gene
Cluster 3.0 [12].
In addition to the pathway signatures of Bild and associates
[6], four additional pathways were studied; however, they were
analyzed by using a different method. Specifically, we used the
estrogen-regulated genes from Oh and colleagues [13], the
52-gene TP53 mutation signature from Troester and associ-
ates [14], the HER1 pathway 2 signature from Hoadley and
colleagues [15], and the proliferation signature from Whitfield
and others [16]. Each set of genes was split into those
induced or repressed in the experimental state of the original
publication, and only those features shown to be induced in
the experimental state were considered here. The sample-spe-
cific score for each of these gene sets was assigned as
described in Park and co-workers [17]. The features are stand-
ardized to have a mean of zero and unit variance. The mean of
the features in each set was taken to be the sample specific
score for that pathway.
Chemosensitivity signatures
Because the expression signatures and the patient data were
based on multiple platforms, all these signatures were consol-
idated to the Affymetrix HG-U133A platform by using Chip-
Comparer. An initial training set representing two biologic
states (drug resistant and drug sensitive) constitutes a chem-
osensitivity signature with binary regression methods per-
formed in R/Bioconductor. Class labels (zero or one) were
assigned to those that fall into two distinct clusters. Bayesian
fitting of binary probit regression models to the training data
then permits an assessment of the relevance of the metagene
signatures in within-sample classification, and estimation and
uncertainty assessments for the binary regression weights
mapping metagenes to probabilities. To guard against overfit-
ting, given the disproportionate number of variables to sam-
ples, leave-one-out cross-validation analysis was performed to
test the stability and predictive capability of the model. Predic-
tions of chemosensitivity (in the validation samples involving
the Wang and Miller cohorts) were then evaluated by using
methods previously described [7] producing estimated rela-
tive probabilities and associated measures of uncertainty
across the validation samples. Hierarchic clustering of tumor
predictions was performed by using R/Bioconductor. All the
data analyses were implemented by R/Bioconductor statisti-
cal packages [18] and GraphPad Prism software (GraphPad
Software Inc., La Jolla, CA, USA).
Results
Gene expression subtypes in breast cancer
By using hierarchic clustering of gene-expression data, we
previously showed that breast tumors can be classified into
five major subtypes (Luminal A, Luminal B, HER2-enriched,
Basal-like, Normal Breast-like). Importantly, further work has
shown that these subtypes are reproducible across different
sample sets and can predict relapse-free and overall patient
survival times [1,2,19,20]. For this study, we made use of a
combined data set, as described in Methods, that uses sam-
ples taken from Wang and co-workers [GEO:GSE2034] and
Miller and associates [GEO:GSE3494]. Figure 1a shows a
typical hierarchic clustering using the genes defining the intrin-
sic subtypes. Subtype predictions were generated as
described in Hu and colleagues [2], and these predictions
were in agreement with segregation in the sample dendro-
gram. As expected, the subtype predictions were associated
with relapse-free survival times with the Luminal A and Normal-
like groups indicative of good prognosis (Figure 1b).
The expression characteristics of these subtypes are consist-
ent with previous observations including an HER2+ expression
cluster that is also predominantly ER-, and that contained mul-
tiple genes from the 17q11 amplicon, including HER2/ERBB2
and GRB7. A basal expression cluster also was present and
contained genes (that is, c-KIT, FOXC1, and P-Cadherin) pre-
viously identified to be characteristic of basal epithelial cells. A
Luminal/ER+ expression cluster was present and contained
ER, XBP1, FOXA1, and GATA3. GATA3 was recently shown
to be somatically mutated in some ER+ breast tumors [21].
Patterns of pathway deregulation in breast cancer
The analysis of breast cancer expression data by unsupervised
methods to reveal structure in the data set makes no assump-
tions regarding the underlying biology that might define the
various subtypes. Our recent studies described a strategy
making use of gene-expression signatures that reflect the
activity of various oncogenic signaling pathways that can be
used to characterize the status of important signaling path-
ways in tumors and to relate this to clinical outcome, as well as
the potential for predicting response to targeted therapeutic
agents [4,6,8]. We have now made use of these pathway sig-
natures to aid in characterizing breast cancer subtypes, and
predictions of pathway activation were performed by using
each of the previously described pathway signatures [6]. Addi-
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tional signatures developed independently for HER1 [15], ER
[13], p53 [14] pathways, and a proliferation-signature [16],
were used as described in the Methods section and also were
tested. These results are displayed as a heat map reflecting
the relative activity of each pathway, in which red represents
high activity (Figure 1c), with samples clustered according to
these probabilities (ER and proliferation were excluded from
the cluster analysis, but are shown for reference purposes).
Three prominent clusters of samples/tumors were identified by
this analysis. As one measure of the relevance of the patterns
of pathway activation, we examined the clinical outcome of
patients identified by these patterns of pathway activation. As
shown in Figure 1d, these patterns of pathway activity segre-
gate samples into clinically relevant groups, as assessed by
relapse-free survival (P = 0.007). The survival curves of the dif-
ferent groups appear similar to the subtype grouping, and in
fact, the segregation of samples by pathway activity is signifi-
cantly associated with intrinsic subtype (Figure 1e). This result
also suggests that subtype identity is attributable, at least in
part, to activation of some of these pathways.
Dissection of intrinsic subtypes using signatures of 
pathway deregulation
Although the division of breast cancers into the five subtypes
defined by expression data is a clear first step in dissecting the
heterogeneity of breast cancer, it also is likely that dissection
within each subtype would further our understanding of breast
tumor heterogeneity. Moreover, rather than using the gene-
expression data or the pathway-signature data to define sub-
types as parallel analyses, the real opportunity lies at the inter-
section of these two approaches, by using them in a
complementary fashion. In the example shown in Figure 2a and
quantified in Figure 2b, it is evident that distinct patterns of
pathway activation can be seen as a function of subtype. For
example, high predicted activity of RAS, CTNNB1 (E-catenin),
TP53, and HER1 pathways was associated with the Basal-like
subtype, in some cases consistent with previous observations
[22-24]. Additionally, RAS pathway activation was seen in
Figure 1
Dissection of breast cancer heterogeneity by using intrinsic subtypes and pathway patternst i   i  i tri si  subtypes and path ay pat erns. (a) Hierarchic cluster analysis from a combined dataset 
comprising 537 samples. The centroid subtype predictions are shown immediately below the dendrogram with red for Basal-like, green for Normal-
like, Luminal A as dark blue, Luminal B as light blue, and pink as HER2-enriched. (b) Kaplan-Meier survival plot for relapse-free survival by using the 
centroid predictions. (c) Cluster analysis of pathway-activation status predictions with red indicating active status, black, average pathway status, 
and green, low to absent pathway-activation status. (d) Kaplan-Meier survival plot based on the clustering of pathways from (c). (e) Correlations 
between tumor subtype (a) and groupings based on pathway status (c).
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Basal-like, HER2-enriched, and Normal-like subytpes,
whereas both Luminal A and Luminal B subtypes have low pre-
dicted RAS activity. Additionally, the highest E2F activity was
seen in the Basal-like, HER2-enriched, and Luminal B sub-
types, which is consistent with their higher proliferation rates
compared with Luminal A and Normal-like tumors. Thus, our
combining of distinct signatures onto a common test set has
recapitulated known relations and identified new ones. Also,
the Basal-like, HER2-enriched, and Luminal B subtypes are
characterized by activation of multiple pathways in contrast to
the Luminal A subtype, which show low predicted activity for
most oncogenic pathways in this study.
These analyses were carried out with a set of samples that
were combined from two separate data sets. Analysis of the
results of pathway predictions in each data set separately
demonstrated a close agreement in the patterns observed
(Figure 2c), thus emphasizing the robustness of the measures.
In addition, predictions of pathway activities in a third inde-
pendent data set provided further confirmation for the patterns
of pathway activity typical of a given intrinsic subtype [see
Additional data file 1].
Each pathway also was examined for significance in univariate
survival analysis across all patients, and within subtypes. The
MYC, TP53, and proliferation signatures were significant pre-
dictors of outcomes across all patients and within the Luminal
B and HER2-enriched subtypes. The ER and HER1 pathway
signatures were prognostic across all patients, but ER was
significant only within the Luminal B subtype, and HER1
trended toward significance in Luminal B (Table 1) with some
showing significance for both (Table 1).
Although specific pathways exist with an overall elevation in
each subtype, it is clear that pathway status is not simply a
function of intrinsic subtype. As is evident from Figure 2, het-
Figure 2
Pathway-activation status patterns are characteristic of intrinsic subtypes. (a) Heat maps of scaled pathway-activation scores in which the subjects 
are ordered according to their predicted subtype. The pathway-activation status of different pathways is displayed for the combined dataset, with 
strong pathway activation displayed by red, average status by black, and low to absent pathway activation by green. (b) Box-and-whisker plot show-
ing pathway activation as a function of subtype displayed for the combined dataset. (c) Comparison of pathway activation as a function of subtype in 
the two datasets.
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erogeneity exists when one examines each pathway pattern
within a subtype. Heterogeneity of pathway status is the most
evident within the Basal-like tumors, which demonstrate rela-
tively large variation in the activation of many pathways. The
Luminal B samples also encompass a broad range of activity
across multiple pathways, but to a lesser extent than the
Basal-like samples. Luminal A and Normal-like samples give
the lowest variation in activity across the pathways.
Previous work showed that the prediction of pathway activa-
tion can coincide with sensitivity to drugs that target a compo-
nent of the pathway [8,25,26]. As such, this information
 provides an opportunity to identify new therapeutic options for
these patients by providing a potential basis for guiding the
use of pathway-specific drugs. Therefore, we next focused on
this heterogeneity as a mechanism to identify potential thera-
peutic opportunities that might be unique for individual sub-
types. In particular, we examined the patterns of pathway
activation in both the Luminal B and Basal-like subtypes, which
represent patients with a poor prognosis and the need for new
therapeutic approaches. In particular, we examined whether
specific pathways had inverse or compensatory patterns
within a subtype that could provide alternative therapeutic
opportunities for patients. We found multiple instances in
which patients exhibited inverse relations of activation of one
pathway versus another. These results include complementary
patterns for HER1 and PI3K, as well as for HER1 and SRC in
the Luminal B data subtype (Figure 3a and 3b). Likewise, the
HER1 and SRC pathways, or the HER1 and RAS pathways,
show complementary patterns in the Basal-like subtype, in
which patients exhibit activity of either pathway independent of
the other (Figure 3C and 3D). Taken together, these analyses
demonstrate that each of the intrinsic breast cancer subtypes
associates with specific patterns of pathway activation. The
pathways with highest correlation to the intrinsic breast cancer
subtypes include TP53 and HER1. Additionally, oncogenic
pathways can have high variability of activity within a specific
subtype, such as MYC, E2F3 and SRC, reflecting biology
independent of common clinical factors.
Genomic signatures that predict response to cytotoxic 
chemotherapeutics
A further opportunity for identifying novel therapeutic opportu-
nities makes use of a collection of expression signatures
developed to predict sensitivity to commonly used cytotoxic
chemotherapeutic agents. By using dose-response informa-
tion and matched expression data on the NCI-60 cell lines, we
developed a panel of gene-expression signatures representing
resistant and sensitive patterns for a series of cytotoxic agents
commonly used in the treatment of solid tumors, including
breast cancer [7]. Further work has shown that several of
these predictors can accurately predict the response to the
drugs in patients [7,8,27].
We made use of these chemotherapy-response signatures to
predict the likely sensitivity to these agents within these two
breast cancer sample sets. Again, we focused on the Basal-
like and Luminal B subgroups, given the need for new and
novel therapeutic options for these patients. As shown in Fig-
ure 4, both the Basal-like and Luminal B subtypes exhibited
predicted sensitivity to many of the commonly used cytotoxic
agents. Perhaps most important, clear evidence of heteroge-
neity was found within each of these subgroups with respect
to predicted sensitivity to these drugs. These data provide a
further indication of the heterogeneity of tumors within the sub-
types, underscoring the need to focus on this heterogeneity
and to identify therapeutic options tailored to the individual
patient. In addition, the analysis also suggests opportunities
for matching drugs with patients with similar inverse relations
as seen with the pathway signatures. For example, in the
Basal-like subtype, patients that are predicted to be sensitive
to doxorubicin (Adriamycin) are predicted to be resistant to
topotecan, and vice versa. An additional opportunity afforded
by the availability of signatures predicting sensitivity for multi-
ple cytotoxic agents, as well as pathway activation, is the iden-
tification of potential combinatorial strategies that would
derive from overlaps in the predicted sensitivities.
Discussion
Since the advent of chemotherapy to treat cancer, numerous
advances have been made in the development, selection, and
application of these agents; sometimes with remarkable suc-
cesses, as seen in the case of combination chemotherapy for
lymphomas or platinum-based therapy for testicular cancers.
Present-day therapeutic regimens derive from prospective
Table 1
Univariate association of pathway deregulation with disease-
free survival
Pathway Overall LumA LumB Her2 Basal
Ras 0.64 0.081 0.6 0.75 0.87
Myc 0.0033 0.92 0.0091 0.037 0.7
E2F3 1.8E-04 0.55 0.0044 0.13 0.13
Bcat 0.22 0.43 0.084 0.64 0.56
Src 0.85 0.79 0.29 0.32 0.7
NP63 0.93 0.21 0.83 0.73 0.19
PI3K 0.72 0.12 0.82 0.84 0.15
p53mut 6.0E-06 0.15 0.0014 0.037 0.77
Her1 1.5E-04 0.12 0.077 0.11 0.98
ER 3.9E-04 0.15 0.001 0.083 0.078
Proliferation 3.0E-05 0.088 0.0035 0.046 0.76
P values of the pathway coefficient when predicting disease-free 
survival (Cox proportional hazard P values). The pathways with 
significant relapse-free survival associations are indicated in italics; 
these were tested across all patients, and across all patients within 
each subtype separately.
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clinical studies that evaluate the relative effectiveness of regi-
mens for groups of patients. Importantly, these studies by
necessity have used largely unselected populations of
patients and thus represent effective regimens for the group,
but not necessarily for any one individual patient. In short, it is
clear that breast cancer is not a single disease but rather a col-
lection of diseases with unique characteristics. Individualizing
treatments by identifying patients who will or will not respond
to specific agents will potentially increase the overall effective-
ness of these drugs and limit the incidence and severity of tox
icities that impair the functional status of patients and their
ability to tolerate further therapies.
Toward this goal, we have used gene-expression profiles
derived from DNA microarray analysis to dissect the heteroge-
neity evident within human breast cancers. This includes the
ability to identify subtypes of cancer that can be associated
with distinct clinical characteristics and outcomes, and the
ability to assay for the activity of specific signaling pathways.
The value in these studies is to identify disease subtypes that
represent more homogeneous collections of tumors and
patients, so as the better to approach opportunities for individ-
ualized therapeutics. The results we present here extend our
initial observations several important steps by combining com-
plementary methods to characterize further the intrinsic sub-
types with respect to pathway activation and potential
chemotherapy sensitivities.
With the goal of identifying therapeutic opportunities that
match the characteristics of individual breast cancer patients,
we primarily focused on the Basal-like and Luminal B sub-
types, given the poor prognosis of these groups of patients.
Moreover, given the fact that the Basal-like subtype is charac-
terized as HER2-not amplified, PR- and ER-, existing therapeu-
tic opportunities are limited. Our analysis from using both
Figure 3
Inverse relations in pathway activation in Basal-like and Luminal B subtypes. Pathway-activation patterns are shown for (a, b) Basal-like, and (c, d) 
Luminal B subtypes. Relative pathway-activation status is shown on the y-axis, whereas each location on the x-axis represents an individual tumor.
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pathway profiles and chemotherapy-sensitivity profiles sug-
gests multiple possible strategies for therapeutic opportuni-
ties in Basal-like and Luminal B patients. A large fraction of the
Basal-like subgroup exhibits HER1 pathway activation, which
we have observed before by using other data sets [15], and
which could be matched with a variety of EGFR inhibitors; in
fact, clinical trials using HER1 inhibitors on metastatic "triple-
negative/basal-like" patients are under way (ClinicalTrials.gov
Identifier: NCT00232505 and NCT00248287); these find-
ings lend strong support to our approach and suggest the
potential for a general strategy of using patterns of pathway
 activation as a means of identifying therapeutic opportunities.
Interestingly, it is also clear that an inverse pattern of pathway
deregulation exists for HER1 and the SRC pathways, as well
as for HER1 and RAS pathways within the Basal-like subtype,
suggesting an opportunity to direct therapy, either HER1 spe-
cific, SRC specific, or RAS specific, as a function of these
pathway profiles. The Basal-like subtype is also enriched for 
tumors predicted to be sensitive to doxorubicin, and a comple-
mentary pattern was found with predicted sensitivity to topo-
tecan, suggesting additional opportunities for combination
therapies that might be effective in this subtype.
The Luminal B subtype also was characterized by activation of
the HER1 pathway along with complementary activation of the
PI3K pathway or SRC pathway. Many agents in development
target PI3K or SRC, and further options exist for activities
downstream of the action of PI3K, such as AKT1 and mTOR.
A fraction of the Luminal B tumors were also predicted to be
sensitive to doxorubicin, although less so than for the Basal-
like subtype. Nevertheless, a complementary sensitivity exists
with etoposide, suggesting an opportunity to make use of
these two agents.
Conclusions
We believe that our studies could guide the development of
prospective clinical studies that would evaluate the efficacy of
therapeutic regimens, based on a combined pattern of path-
way and chemosensitivity within a given subtype (Figure 5).
The initial stratification would be on the intrinsic subtype clas-
Figure 4
Chemotherapeutic sensitivity profiles for Luminal B and Basal-like subtypes. Heat maps of scaled chemotherapeutic-sensitivity predictions in the 
combined dataset for (a) Luminal B and (b) Basal–like subtypes are shown. Samples were clustered, based on the predicted sensitivities.
Figure 5
Schematic diagram of a potential genomics-guided trial based on intrin-si  subtype and pathw y sig atures
sic subtype and pathway signatures.
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sification, with further dissection based on pathway or chemo-
sensitivity signatures or both, with the latter two providing
guidance in the choice of therapeutics. Given the poor prog-
nosis and the lack of current therapeutic options, we believe
that a focus on the Basal-like and Luminal B subtypes is of
highest priority.
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